Canopy Growth Announces Sale of Stake in AusCann The companies will continue to collaborate in the Australian market

Canopy Growth Announces Sale of Stake

The companies will continue

to collaborate in the Australian market

SMITHS FALLS, ON, Oct. 15, 2019 /CNW/ - Canopy

Growth Corporation (TSX: WEED) (NYSE: CGC) ("Canopy Growth") has sold its 42,087,639 shares in Australian cannabis company

AusCann Group Holdings (AusCann) via an off market block trade at $0.15 per share for gross proceeds of $6.3 million. The trade

was facilitated by Canaccord Australia.

The sale represents Canopy Growth's total 13.2%

interest in AusCann.

"Canopy Growth remains optimistic about

the future of the Australian medical cannabis market and will continue to collaborate with the team at Auscann to support greater

physician understanding and patient access to high quality cannabis products throughout Australia," said Mark Zekulin, CEO,

Canopy Growth. "The decision to divest our position in AusCann, which we obtained three years ago in exchange for support

provided, will allow us to sharpen our focus on our wholly-owned operations in the market, while continuing to collaborate with

our partners at AusCann."

Dr. Marcel Bonn-Miller, Canopy Growth's Global

Senior Director of Clinical Science, will continue to sit on the AusCann Board of Directors to facilitate future collaboration.

Here's to Future Growth.

About Canopy Growth Corporation

Canopy Growth (TSX:WEED, NYSE:CGC) is a world-leading diversified cannabis, hemp and cannabis device company, offering distinct

brands and curated cannabis varieties in dried, oil and Softgel capsule forms, as well as medical devices through Canopy Growth's

subsidiary, Storz & Bickel GMbH & Co. KG. From product and process innovation to market execution, Canopy Growth is driven

by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time.

Canopy Growth has operations in over a dozen countries across five continents.

Canopy Growth's medical division, Spectrum

Therapeutics is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the

public's understanding of cannabis, and has devoted millions of dollars toward cutting edge, commercializable research and IP development.

Spectrum Therapeutics sells a range of full-spectrum products using its colour-coded classification Spectrum system as well as

single cannabinoid Dronabinol under the brand Bionorica Ethics.

Canopy Growth operates retail stores across

Canada under its award-winning Tweed and Tokyo Smoke banners. Tweed is a globally recognized cannabis brand which has built a large

and loyal following by focusing on quality products and meaningful customer relationships.

From our historic public listing on the Toronto

Stock Exchange and New York Stock Exchange to our continued international expansion, pride in advancing shareholder value through

leadership is engrained in all we do at Canopy Growth. Canopy Growth has established partnerships with leading sector names including

cannabis icons Snoop Dogg and Seth Rogen, breeding legends DNA Genetics and Green House Seeds, and Fortune 500 alcohol leader Constellation

Brands, to name but a few. Canopy Growth operates eleven licensed cannabis production sites with over 4.7 million square feet of

production capacity, including over one million square feet of GMP certified production space. For more information visit www.canopygrowth.com

Notice Regarding Forward Looking Statements

This news release contains "forward-looking statements" within the meaning of the United States Private Securities

Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities

legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans",

"expects" or "does not expect", "is expected", "estimates", "intends", "anticipates"

or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions,

events or results "may", "could", "would", "might" or "will" be taken, occur

or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which

may cause the actual results, performance or achievements of Canopy Growth or its subsidiaries to be materially different from

any future results, performance or achievements expressed or implied by the forward-looking statements or information contained

in this news release. Examples of such statements include statements with respect to divesting shares. Risks, uncertainties and

other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities

to differ materially from those expressed or implied by such forward-looking information, including the Company's ability to satisfy

provincial sales contracts or provinces purchasing all cannabis allocated to them, and such risks contained in the Company's annual

information form dated June 25, 2019 and filed with Canadian securities regulators available on the Company's issuer profile on

SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information

or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and

no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information and

forward-looking statements included in this news release are made as of the date of this news release and the Company does not

undertake an obligation to publicly update such forward-looking information or forward-looking information to reflect new information,

subsequent events or otherwise unless required by applicable securities laws.

View original content to download multimedia:http://www.prnewswire.com/news-releases/canopy-growth-announces-sale-of-stake-in-auscann-300938548.html

SOURCE Canopy Growth Corporation

View original content to download multimedia:

For further information: Caitlin O'Hara, Media Relations,

Caitlin.Ohara@canopygrowth.com, 613-291-3239; Investor Relations, Tyler Burns, Tyler.Burns@canopygrowth.com, 855-558-9333 ext.

CO: Canopy Growth Corporation

CNW 07:30e 15-OCT-19